New Two-Pronged cancer drug enters human testing
NCT ID NCT07172802
Summary
This early-stage study is testing a new drug called GI-108 in people with advanced or spreading solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The main goals are to find a safe dose and see if the drug shows any signs of helping to shrink tumors. The drug is designed to work by boosting the body's immune system to fight cancer in two different ways.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
Contact Email: •••••@•••••
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yonsei University Health System, Severance Hospital
RECRUITINGSeoul, 03722, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.